Market Cap: $904.56M
Market Cap: $904.56M
Open
$23.94
Prev. Close
$18.27
High
$24.45
Low
$23.51
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues.
Artivion, Inc. trades on the New York Stock Exchange under the ticker AORT, priced in USD.
Artivion, Inc. has a market capitalisation of $904.56M, based on its latest share price.
AORT has no meaningful P/E ratio because it reported a loss over the last 12 months.
Over the past 52 weeks AORT has traded between $18.11 and $48.25.
No. Artivion, Inc. does not currently pay a dividend.
Loss-making over the last 12 months (net margin -3.7%).
The analyst consensus rating for AORT is Buy. Analysts' average 12-month price target of $40.88 implies 120% upside.
James Patrick Mackin is the CEO of Artivion, Inc., which is headquartered in Kennesaw.
Generated automatically from reported financial data. General information only, not financial advice.

Artivion, Inc. (Ticker: AORT) receives FDA approval for its AMDS Hybrid Prosthesis, a significant development in the treatment of acute Debakey Type I aortic dissections with malperfusion. This innova…

Artivion (Ticker: AORT) addresses a critical juncture in its growth narrative against the backdrop of its latest financial report. Revenue Growth Amid Profitability Concerns The company experiences a…
Artivion, Inc. (Ticker: AORT) has reported significant achievements alongside notable challenges following its latest financial disclosures. In the first quarter of 2026, the company showcases a reven…

In a significant advancement within the cardiovascular device sector, Artivion, Inc. receives FDA approval for the Premarket Approval (PMA) of the NEXUS Aortic Arch System, developed by Endospan. This…